

1 **Supplementary Materials and Methods**

2

3 Component Analysis of Multi-Purpose Contact Lens Solutions to Enhance Activity
4 Against *Pseudomonas aeruginosa* and *Staphylococcus aureus*

5

6 Leo Lin, Janie Kim, Hope Chen, Regis Kowalski, Victor Nizet

7

8 **Supplementary Figure Legends**

9

10 Fig. S1. **The antibacterial efficacy of multi-purpose contact lens solutions against**
11 **clinical keratitis isolates of *S. aureus* (A-C) and *P. aeruginosa* (D-F).** Contact lens
12 solutions were serially diluted in cation-adjusted Muller Hinton broth and minimal
13 inhibitory concentration (MIC) was determined by CLSI broth microdilution methodology.
14 FQs = Fluoroquinolone sensitive. FQr = Fluoroquinolone resistant. All data points were
15 done in duplicate and are representative of 2 independent experiments.

16

17 Fig. S2. **CHD and EDTA have synergistic activity against clinical keratitis isolates**
18 **of *P. aeruginosa*.** (A-C) Checkerboard assays testing the combination of CHD and
19 EDTA against *P. aeruginosa*. Resazurin probe was used to assess bacterial viability:
20 blue color - no viable bacteria; red color - viable bacteria. Blue wells bounded by the
21 green bars in the bottom right quadrant of the plate all have FIC values <0.5 Green box
22 demarks well with no viable bacteria with a $\sum FIC < 0.13$ indicating synergy of CHD and

23 EDTA against *P. aeruginosa* . FQs = Floroquinolone sensitive. FQr = Floroquinolone
24 resistant. Data representative of 2 independent experiments.

25

26 Fig. S3. **ISO 14729 assay conducted with C30/P5/E5000 against clinical keratitis**
27 **isolates**. Reduction in bacteria concentrations after 1 hour incubation in a phosphate
28 buffered saline solution containing CHD 30 PPM, PAPB 5 PPM, and EDTA 5,000 PPM.
29 ISO 14729 testing guidelines were followed. Data plotted are mean \pm SEM and
30 represent the average of 2 independent experiments.

Figure S1





Figure S2

P. aeruginosa keratitis isolates Checkerboard assays




Figure S3

ISO 14729: Reduction in bacterial concentration in 1 h
Clinical keratitis isolates, C30/P5/E5000

